Bavarian Nordic A/S (OTCMKTS:BVNRY) Stock Passes Below 200-Day Moving Average - Should You Sell?

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $8.88 and traded as low as $7.48. Bavarian Nordic A/S shares last traded at $7.54, with a volume of 1,791 shares traded.

Bavarian Nordic A/S Price Performance

The company has a 50 day simple moving average of $7.70 and a 200-day simple moving average of $8.80. The firm has a market cap of $1.79 billion, a PE ratio of 10.99 and a beta of 1.55.

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.07. The company had revenue of $299.48 million during the quarter, compared to analysts' expectations of $264.06 million. Bavarian Nordic A/S had a net margin of 18.33% and a return on equity of 10.65%. On average, sell-side analysts predict that Bavarian Nordic A/S will post 0.67 EPS for the current fiscal year.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.